[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. You JH, Lee GC, So RK, Cheung KW, Hui M: Linezolid versus vancomycin for prosthetic joint infections: a cost analysis. Infection; 2007 Jun;35(4):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linezolid versus vancomycin for prosthetic joint infections: a cost analysis.
  • BACKGROUND: Prosthetic joint infections (PJIs) caused by methicillin-resistant gram-positive bacteria are primarily treated by intravenous vancomycin.
  • Linezolid, active against methicillin-resistant strains and available in oral and intravenous dosage forms, is a potential alternative to vancomycin for the treatment of PJIs.
  • OBJECTIVE: To analyze the cost of linezolid therapy (outpatient setting) and vancomycin therapy (inpatient and outpatient settings) for PJIs caused by methicillin-resistant gram-positive bacteria.
  • METHODS: A decision tree was designed to simulate the clinical outcome and healthcare resource utilization of linezolid, vancomycin by outpatient and home parenteral antimicrobial therapies (OHPAT) and vancomycin administered in inpatient setting (rehabilitation facility) for patients with PJIs caused by methicillin-resistant strains.
  • The clinical treatment success rates of vancomycin and linezolid were influential factors.
  • Monte Carlo 10,000 simulations showed that the vancomycin (OHPAT) group was less costly than the arms of linezolid and vancomycin (rehabilitation) 64% and 100% of the time, respectively.
  • The linezolid group was less costly than the vancomycin (rehabilitation) group in 65%of the times.
  • CONCLUSION: Home-infusion of vancomycin therapy appears to be the least costly treatment approach for PJIs caused by methicillin-resistant gram-positive bacteria from the perspective of a Hong Kong public health organization.
  • [MeSH-major] Acetamides. Anti-Bacterial Agents. Health Care Costs / statistics & numerical data. Oxazolidinones. Prosthesis-Related Infections. Vancomycin
  • [MeSH-minor] Administration, Oral. Algorithms. Costs and Cost Analysis. Gram-Positive Bacterial Infections / drug therapy. Gram-Positive Bacterial Infections / economics. Home Care Services / economics. Humans. Infusions, Intravenous / economics. Joint Prosthesis / microbiology. Linezolid. Methicillin Resistance / genetics

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. LINEZOLID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646907.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Acetamides; 0 / Anti-Bacterial Agents; 0 / Oxazolidinones; 6Q205EH1VU / Vancomycin; ISQ9I6J12J / Linezolid
  •  go-up   go-down


2. Ikediobi ON, Reimers M, Durinck S, Blower PE, Futreal AP, Stratton MR, Weinstein JN: In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol Cancer Ther; 2008 Jun;7(6):1337-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource.
  • Using a pharmacogenomic approach, we analyzed the relationship between drug activity and mutations in those 11 genes (APC, RB1, KRAS, NRAS, BRAF, PIK3CA, PTEN, STK11, MADH4, TP53, and CDKN2A).
  • Phenothiazines have been used as antipsychotics and as adjunct antiemetics during cancer chemotherapy and more recently have been reported to have anticancer properties.
  • To follow up on the initial pharmacologic observations in the NCI-60 screen, we did pharmacologic experiments on 11 of the NCI-60 cell lines and, prospectively, on an additional 24 lines.
  • The findings reported here have potential implications for the use of phenothiazines in the treatment of V600E BRAF mutant melanoma.
  • [MeSH-major] Codon / genetics. Melanoma / drug therapy. Mutation / genetics. Phenothiazines / therapeutic use. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Amino Acid Substitution. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Screening Assays, Antitumor. Glutamic Acid / genetics. Humans. Mutant Proteins / metabolism. Proto-Oncogene Proteins c-raf / metabolism. Reproducibility of Results. Valine / genetics. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. L-Valine .
  • Hazardous Substances Data Bank. PHENOTHIAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Mar;24(3):227-35 [10700174.001]
  • [Cites] Leuk Res. 2008 May;32(5):709-16 [17942153.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 18;283(4):726-31 [11350043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10787-92 [11553813.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):785-93 [15120034.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):117-27 [15324695.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):129-37 [15324696.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] J Med Chem. 2002 Feb 14;45(4):818-40 [11831894.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jul;1(7):493-502 [12120256.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1000-11 [12615715.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4340-6 [14555504.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34 [14623978.001]
  • [Cites] Genome Biol. 2003;4(12):R82 [14659019.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):463-76 [14706338.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] J Natl Cancer Inst. 1989 Jul 19;81(14):1088-92 [2738938.001]
  • [Cites] J Biol Regul Homeost Agents. 1991 Apr-Jun;5(2):52-8 [1910248.001]
  • [Cites] Biochem Pharmacol. 1992 Jan 9;43(1):103-7 [1346493.001]
  • [Cites] Science. 1992 Oct 16;258(5081):447-51 [1411538.001]
  • [Cites] Drugs Exp Clin Res. 1994;20(1):13-8 [7924890.001]
  • [Cites] J Natl Cancer Inst. 1994 Dec 21;86(24):1853-9 [7990160.001]
  • [Cites] Science. 1997 Jan 17;275(5298):343-9 [8994024.001]
  • [Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):647-53 [9150955.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4285-300 [9331090.001]
  • [Cites] J Chem Inf Comput Sci. 1998 Mar-Apr;38(2):189-99 [9538518.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):983-98 [16322337.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):853-67 [16648555.001]
  • [Cites] Nat Rev Cancer. 2006 Oct;6(10):813-23 [16990858.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2601-5 [17088435.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2606-12 [17088437.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):820-32 [17339364.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1483-91 [17483436.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):94-104 [17490733.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91 [17666531.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):415-24 [18199535.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):236-44 [10700175.001]
  • (PMID = 18524847.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 077012; United States / Intramural NIH HHS / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Codon; 0 / Mutant Proteins; 0 / Phenothiazines; 3KX376GY7L / Glutamic Acid; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.6.5.2 / ras Proteins; GS9EX7QNU6 / phenothiazine; HG18B9YRS7 / Valine
  • [Other-IDs] NLM/ PMC2705835; NLM/ UKMS5234
  •  go-up   go-down


3. El Helou OC, Berbari EF, Lahr BD, Eckel-Passow JE, Razonable RR, Sia IG, Virk A, Walker RC, Steckelberg JM, Wilson WR, Hanssen AD, Osmon DR: Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis; 2010 Aug;29(8):961-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.
  • The aim of this study was to evaluate the efficacy and safety of rifampin for Staphylococcus aureus (SA) or coagulase negative staphylococci (CNS) prosthetic joint infection (PJI) treated with debridement and retention (D/R).
  • We calculated the treatment failure cumulative incidence (TF) of a cohort of 101 patients with SA or CNS PJI treated with D/R and antimicrobial therapy.
  • Cox proportional hazards regression evaluated the association between treatment and time-to-TF controlling for the propensity to treat with rifampin and temporal confounders.
  • Seven percent (1/14) of the prospective rifampin-treated patients, 32% (10/31) of the historical rifampin-treated patients and 38% (21/56) of the historical non-rifampin treated patients developed TF.
  • None (0/14) of the patients in the prospective study developed hepatotoxicity.
  • The outcome of staphylococcal PJI treated with D/R and rifampin-based regimens was better when compared with a historical cohort treated without rifampin.
  • [MeSH-major] Anti-Bacterial Agents / administration & dosage. Prosthesis-Related Infections / drug therapy. Rifampin / administration & dosage. Staphylococcal Infections / drug therapy. Staphylococcus / isolation & purification
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Debridement. Female. Humans. Liver / drug effects. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 2007 Nov 1;45(9):1113-9 [17918072.001]
  • [Cites] Sci Am. 1981 Oct;245(4):54-63 [7027437.001]
  • [Cites] Clin Infect Dis. 2006 Jan 15;42(2):216-23 [16355332.001]
  • [Cites] Clin Microbiol Infect. 2006 Sep;12(9):930-3 [16882303.001]
  • [Cites] Infection. 2004 Aug;32(4):222-8 [15293078.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12 Suppl 3:93-101 [16669932.001]
  • [Cites] J Bone Joint Surg Am. 2007 Mar;89(3):526-33 [17332101.001]
  • [Cites] Clin Microbiol Infect. 2007 Jun;13(6):586-91 [17331125.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Dec;50(12):4011-7 [17015630.001]
  • [Cites] Orthopedics. 1991 Aug;14(8):841-4 [1923965.001]
  • [Cites] Injury. 2006 May;37 Suppl 2:S3-14 [16651069.001]
  • [Cites] J Antimicrob Chemother. 2001 Aug;48(2):253-8 [11481297.001]
  • [Cites] J Antimicrob Chemother. 1997 Feb;39(2):235-40 [9069545.001]
  • [Cites] Lancet. 2001 Jul 14;358(9276):135-8 [11463434.001]
  • [Cites] Clin Infect Dis. 2006 Feb 15;42(4):471-8 [16421790.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):419-30 [11170950.001]
  • [Cites] Acta Orthop. 2007 Dec;78(6):755-65 [18236181.001]
  • [Cites] Am J Med. 2006 Nov;119(11):993.e7-10 [17071171.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1285-92 [15494904.001]
  • [Cites] Mater Manag Health Care. 2006 Jul;15(7):61-2 [16900875.001]
  • (PMID = 20505968.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; VJT6J7R4TR / Rifampin
  •  go-up   go-down


Advertisement
4. Stebbins JL, De SK, Machleidt T, Becattini B, Vazquez J, Kuntzen C, Chen LH, Cellitti JF, Riel-Mehan M, Emdadi A, Solinas G, Karin M, Pellecchia M: Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A; 2008 Oct 28;105(43):16809-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a new JNK inhibitor targeting the JNK-JIP interaction site.
  • In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes.
  • In view of its favorable inhibition profile, selectivity, and ability to function in the cellular milieu and in vivo, BI-78D3 represents not only a JNK inhibitor, but also a promising stepping stone toward the development of an innovative class of therapeutics.

  • BindingDB. BindingDB .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Nov 1;18(45):6158-62 [10557107.001]
  • [Cites] Diabetes. 2001 Jan;50(1):77-82 [11147798.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):10987-97 [11790767.001]
  • [Cites] Nat Rev Drug Discov. 2003 Jul;2(7):554-65 [12815381.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):420-5 [12901952.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32662-72 [12788955.001]
  • [Cites] Immunity. 2003 Nov;19(5):725-37 [14614859.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2185-95 [15141161.001]
  • [Cites] Nat Med. 2004 Oct;10(10):1128-32 [15448687.001]
  • [Cites] Drug News Perspect. 2004 Sep;17(7):447-53 [15514704.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):17355-63 [2170374.001]
  • [Cites] Cell. 1994 Mar 25;76(6):1025-37 [8137421.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] Genes Dev. 1994 Dec 15;8(24):2996-3007 [8001819.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2760-70 [8654373.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Jan;35(1-2):47-57 [8717339.001]
  • [Cites] J Mol Med (Berl). 1996 Oct;74(10):589-607 [8912180.001]
  • [Cites] Cell. 1996 Nov 29;87(5):929-39 [8945519.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Science. 1997 Aug 1;277(5326):693-6 [9235893.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):F85-104 [9395283.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1740-9 [9501095.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):205-19 [9561845.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1671-4 [9733513.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):609-36 [15722167.001]
  • [Cites] J Biol Chem. 2006 Jun 2;281(22):15258-67 [16571730.001]
  • [Cites] Anal Biochem. 2008 Jan 15;372(2):189-97 [17961489.001]
  • [Cites] Curr Mol Med. 2007 Nov;7(7):674-86 [18045145.001]
  • [Cites] J Med Chem. 2008 Jun 26;51(12):3460-5 [18494454.001]
  • [CommentIn] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):E18; author reply E19 [19204298.001]
  • (PMID = 18922779.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK073274; United States / NIDDK NIH HHS / DK / R24 DK080263; United States / NIDDK NIH HHS / DK / R21DK073274; United States / NIDDK NIH HHS / DK / R24DK080263
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-((5-nitro-2-thiazolyl)thio)-3H-1,2,4-triazol-3-one; 0 / Adaptor Proteins, Signal Transducing; 0 / Dioxanes; 0 / MAPK8IP1 protein, human; 0 / Protein Kinase Inhibitors; 0 / Thiazoles; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ PMC2567907
  •  go-up   go-down


5. Ucar DA, Hochwald SN: FAK and interacting proteins as therapeutic targets in pancreatic cancer. Anticancer Agents Med Chem; 2010 Dec;10(10):742-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FAK and interacting proteins as therapeutic targets in pancreatic cancer.
  • Chemotherapy and radiation therapy have had minimal ability to alter the natural course of the disease.
  • Pancreatic cancer has been found to have several genetic alterations including activation of K-ras and inactivation of p53, p16, and DPC4.
  • Clinicians must translate the available knowledge of the molecular basis of this disease into rationale and effective therapeutic strategies for treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Focal Adhesion Protein-Tyrosine Kinases / metabolism. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / enzymology. Protein Kinase Inhibitors / therapeutic use
  • [MeSH-minor] Animals. Gene Expression Regulation, Neoplastic / drug effects. Humans


6. Hellmark B, Unemo M, Nilsdotter-Augustinsson A, Söderquist B: Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene. Clin Microbiol Infect; 2009 Mar;15(3):238-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene.
  • Staphylococcus epidermidis is the most important pathogen in infections related to implanted foreign materials, especially prosthetic joint infections (PJIs).
  • The aim of this study was to investigate the antimicrobial activities of 16 antibiotics against S. epidermidis isolated from PJIs, with special focus on rifampicin and rpoB variability.
  • The mecA gene was detected in 85% of the isolates.
  • Among the other antibiotics, the rates of resistance varied between 0% (vancomycin) and 82% (trimethoprim-sulphamethoxazole). S. epidermidis strains causing PJIs often show multiresistance, including resistance to rifampicin, which is mainly caused by one or two SNPs.
  • Some of the newer antimicrobial agents may provide alternatives for monotherapy or combination therapy with rifampicin.
  • Detection of mecA is necessary before initiating treatment of infections due to S. epidermidis when it displays intermediate susceptibility to cefoxitin.
  • [MeSH-major] Anti-Bacterial Agents / pharmacology. DNA-Directed RNA Polymerases / genetics. Drug Resistance, Bacterial. Prosthesis-Related Infections / microbiology. Rifampin / pharmacology. Staphylococcal Infections / microbiology. Staphylococcus epidermidis / drug effects
  • [MeSH-minor] Humans. Joint Prosthesis / adverse effects. Microbial Sensitivity Tests / methods

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196261.001).
  • [ISSN] 1469-0691
  • [Journal-full-title] Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
  • [ISO-abbreviation] Clin. Microbiol. Infect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; EC 2.7.7.6 / DNA-Directed RNA Polymerases; EC 2.7.7.6 / RNA polymerase beta subunit; VJT6J7R4TR / Rifampin
  •  go-up   go-down


7. Motycka V, Sákra L, Mencl K, Havlícek K: [Occurrence of yeast infections at a surgical intensive care unit]. Rozhl Chir; 2001 Jun;80(6):320-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Occurrence of yeast infections at a surgical intensive care unit].
  • [Transliterated title] Výskyt kvasinkových infekcí na chirurgické JIP.
  • The authors evaluate the occurrence of candida infections in the surgical intensive care unit (ICU) in a one-year period.
  • From the group of 1798 patients hospitalized in a surgical ICU there are 50 patients (2.8%) with candida colonisation and even 56 patients (3.1%) with candida infection.
  • The authors evaluate risk factors for development of candida infection, its etiologic agents and the most frequent site of infection.
  • In addition to usual treatment the authors suggest pre-emptive therapy in patients with risk factors.
  • In the one-year period, two patients died of multiorgan failure (MOF) in close connection with candida infection (sepsis).
  • The mortality of the group with proved candida infection was 3.57%.
  • [MeSH-major] Candidiasis. Cross Infection
  • [MeSH-minor] Humans. Intensive Care Units. Mycoses / diagnosis. Mycoses / drug therapy. Mycoses / transmission. Retrospective Studies. Risk Factors. Trichosporon

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11482157.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


8. Sunamura M, Egawa S, Fukuyama S, Motoi F, Takeda K, Akada M, Ottomo S, Abe H, Matsuno S: [Chemotherapy for pancreatic cancer]. Gan To Kagaku Ryoho; 2003 Nov;30(12):1901-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for pancreatic cancer].
  • Gemcitabine (GEM) has replaced 5-fluorouracil (5-FU)-based chemotherapy as the standard of care.
  • For locally advanced disease, most recent studies have incorporated GEM into combined-modality therapy.
  • Similarly, in surgically resectable disease, current trials are incorporating GEM into adjuvant therapy.
  • According to several clinical trials it has been demonstrated that improvements in locoregional control and survival may be achieved when chemotherapy using 5-FU is added to radiation for locally advanced pancreatic cancer.
  • The new regimen for locally advanced disease has demonstrated that the better outcome is expected by chemoradiation therapy with 5-FU followed by GEM treatment.
  • In order to develop chemotherapy for pancreatic cancer, we are analyzing mRNA expression of pancreas cancer cell lines and examined their resistant against to GEM.
  • One of the genes is demonstrated to be a responsible for drug sensitivity by clustering analysis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Pancreatectomy. Prognosis. Radiotherapy Dosage. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650957.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  • [Number-of-references] 31
  •  go-up   go-down


9. Saeki H, Sugimasa Y, Yamada R, Akaike M, Takemiya S, Masaki T, Miyagawa K, Okawa S: [Intraoperative radiotherapy (IORT) for unresectable stage IVb pancreatic cancer]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve patients were treated with IORT, 17 with external beam radiotherapy (ERT) and 17 with chemotherapy (CHT, 8 patients doxorubicin-based, 7 patients 5-FU-based).
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Intraoperative Care. Male. Middle Aged. Neoplasm Metastasis. Quality of Life. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484041.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Sieroń A, Hese RT, Sobiś J, Cieślar G: [Estimation of therapeutical efficacy of weak variable magnetic fields with low value of induction in patients with depression]. Psychiatr Pol; 2004 Mar-Apr;38(2):217-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Preliminary results of research on the therapeutical efficacy of weak variable magnetic fields with low value of induction used as magnetostimulation in patients with depression not reacting to two consecutive, correctly applied anti-depressant pharmacological treatment are presented in the paper.
  • In 1 group (11 persons--9 women and 2 men) magnetostimulation with the use of a weak variable magnetic field with a low value of induction of 15 microT generated by the VIOFOR JPS device (Poland) lasting 12 minutes daily for 15 days was added to pharmacological therapy.
  • CONCLUSIONS: It was concluded that adding magnetostimulation to pharmacological therapy results in a progressive, significant reduction of intensification of depression symptoms.
  • [MeSH-major] Antidepressive Agents, Second-Generation / administration & dosage. Depressive Disorder / physiopathology. Depressive Disorder / therapy. Magnetics / therapeutic use
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Electromagnetic Fields. Female. Fluvoxamine / administration & dosage. Humans. Male. Middle Aged. Paroxetine / administration & dosage. Severity of Illness Index. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Depression.
  • Hazardous Substances Data Bank. PAROXETINE HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15307288.001).
  • [ISSN] 0033-2674
  • [Journal-full-title] Psychiatria polska
  • [ISO-abbreviation] Psychiatr. Pol.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; 41VRH5220H / Paroxetine; O4L1XPO44W / Fluvoxamine
  •  go-up   go-down


11. Dong Z, Zhou L, Del Villar K, Ghanevati M, Tashjian V, Miller CA: JIP1 regulates neuronal apoptosis in response to stress. Brain Res Mol Brain Res; 2005 Apr 4;134(2):282-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, under certain stress conditions, down-regulation of JIP1 expression makes neurons more susceptible to apoptosis, suggesting JIP may serve as an anti-apoptosis factor.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Apoptosis / physiology. Gene Expression Regulation / physiology. Neurons / metabolism. Stress, Physiological / pathology
  • [MeSH-minor] Animals. Animals, Newborn. Anoxia / drug therapy. Anoxia / metabolism. Blotting, Western / methods. Caspase 3. Caspases / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Enzyme Inhibitors / pharmacology. Hippocampus / cytology. Humans. Immunohistochemistry / methods. Indoles. MAP Kinase Kinase 7 / metabolism. Mice. Mitogen-Activated Protein Kinase 10 / metabolism. Neuroblastoma. Organ Culture Techniques. Proto-Oncogene Proteins c-jun / metabolism. Rats. Rats, Sprague-Dawley. Time Factors. Transfection / methods. Ultraviolet Rays / adverse effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15836924.001).
  • [ISSN] 0169-328X
  • [Journal-full-title] Brain research. Molecular brain research
  • [ISO-abbreviation] Brain Res. Mol. Brain Res.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 5R37MH39145; United States / NINDS NIH HHS / NS / 5T32NS07149; United States / NIA NIH HHS / AG / AG05142; United States / NIA NIH HHS / AG / AG18879
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Enzyme Inhibitors; 0 / Indoles; 0 / MAPK8IP1 protein, human; 0 / Proto-Oncogene Proteins c-jun; 47165-04-8 / DAPI; EC 2.7.1.- / MAP2K7 protein, human; EC 2.7.1.- / Mitogen-Activated Protein Kinase 10; EC 2.7.12.2 / MAP Kinase Kinase 7; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Casp3 protein, rat; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


12. Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Uchiyama K, Yamaue H: Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer? J Surg Oncol; 2006 May 1;93(6):485-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
  • In our study, we investigated whether postoperative chemotherapy improved survival in patients with invasive ductal carcinoma of the pancreas.
  • Between 1987 and 2004, 111 patients underwent pancreatic resection against invasive ductal carcinoma of the pancreas in Wakayama Medical University Hospital.
  • Median survival time (MST) was 19.4 months, 8.6 months, and 7.2 months, in JPS Stage III (UICC Stage IIA and IIB), JPS Stage IVa (UICC Stage IIA and IIB), and JPS Stage IVb (UICC Stage IV), respectively (P < 0.01).
  • The MST of the chemotherapy group was 12 months, and the MST of the non-chemotherapy group was 8.4 months (P < 0.05).
  • Moreover, in JPS Stage IV (UICC Stage IIA, IIB, III, and IV) highly advanced pancreatic cancer, the MST of the chemotherapy group was 10.9 months, and the MST of the group without chemotherapy was 6.6 months (P < 0.01).
  • Since pancreatic cancer is characterized by an aggressive tumor with a high recurrent rate, postoperative chemotherapy is effective for an improvement of survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Pancreatic Ductal / drug therapy. Pancreatectomy / mortality. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16615151.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Kuan CY, Burke RE: Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy. Curr Drug Targets CNS Neurol Disord; 2005 Feb;4(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the JNK signaling pathway for stroke and Parkinson's diseases therapy.
  • This unique property makes JNK signaling a promising target for developing pharmacological intervention.
  • The inhibitors of the JNK signaling pathway include upstream kinase inhibitors (for example, CEP-1347), small chemical inhibitors of JNK (SP600125 and AS601245), and peptide inhibitors of the interaction between JNK and its substrates (D-JNKI and I-JIP).
  • [MeSH-minor] Alzheimer Disease / drug therapy. Alzheimer Disease / enzymology. Animals. Cell Death / drug effects. Cell Death / physiology. Drug Design. Humans

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • MedlinePlus Health Information. consumer health - Stroke.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723614.001).
  • [ISSN] 1568-007X
  • [Journal-full-title] Current drug targets. CNS and neurological disorders
  • [ISO-abbreviation] Curr Drug Targets CNS Neurol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  • [Number-of-references] 46
  •  go-up   go-down


14. Sobiś J, Jarzab M, Hese RT, Sieroń A, Zyss T, Gorczyca P, Gierlotka Z, Pudlo R, Matysiakiewicz J: Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression. J Affect Disord; 2010 Jun;123(1-3):321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression.
  • BACKGROUND: The aim of this prospective study was to verify whether magnetostimulation with weak variable magnetic fields with low value of induction could enhance the effects of pharmacological therapy in drug-resistant depression.
  • MATERIALS AND METHODS: Thirty patients, 26 women and 4 men, with drug-resistant depression were enrolled in the study.
  • I (14 patients) were given fluvoxamine and treated with weak variable magnetic field using the VIOFOR JPS device; the subjects from Group No.
  • II (16 patients) were also given fluvoxamine but they were treated with the VIOFOR JPS device in placebo mode.
  • RESULTS: After 15 days of treatment highly significant differences were revealed between the patients treated with magnetic field and the patients treated with placebo: the final HDRS score was 53% of the initial value for the group receiving combined treatment, and 86% in the placebo group (p<0.001); for MADRS score the values were 51% and 88% (p<0.001), respectively, and for BDI 60% and 87% (p<0.001).
  • 15% reduction of symptoms, while the concurrent application of magnetic field and SSRI treatment resulted in a 40-50% improvement.
  • CONCLUSION: Our study indicates that adding a two-week low-induction variable magnetic field stimulation to a classical pharmacologic therapy reduces the intensity of symptoms in patients with drug-resistant depressive disorders.
  • [MeSH-major] Antidepressive Agents, Second-Generation / therapeutic use. Depressive Disorder, Major / therapy. Fluvoxamine / therapeutic use. Transcranial Magnetic Stimulation / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance. Female. Humans. Male. Middle Aged. Personality Inventory. Prospective Studies

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19896204.001).
  • [ISSN] 1573-2517
  • [Journal-full-title] Journal of affective disorders
  • [ISO-abbreviation] J Affect Disord
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antidepressive Agents, Second-Generation; O4L1XPO44W / Fluvoxamine
  •  go-up   go-down


15. Estes CS, Beauchamp CP, Clarke HD, Spangehl MJ: A two-stage retention débridement protocol for acute periprosthetic joint infections. Clin Orthop Relat Res; 2010 Aug;468(8):2029-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-stage retention débridement protocol for acute periprosthetic joint infections.
  • BACKGROUND: Due to the historically poor infection control rates with débridement and component retention for acute periprosthetic infections we developed a new approach for treating acute periprosthetic total joint infections: initial débridement with prosthesis retention and placement of antibiotic-impregnated cement beads followed by a second débridement within 7 days, at which time the beads are removed and new modular parts inserted.
  • QUESTIONS/PURPOSES: We determined the ability of this two-stage débridement to control infection.
  • METHODS: We retrospectively reviewed the charts of 20 patients who underwent this technique; 2 had postoperative and 18 had hematogenous infections.
  • The primary outcome measure was the infection control.
  • RESULTS: Two of the 20 patients had persistent infection.
  • Of the 18 patients without evidence of persistent infection, 10 were no longer on antibiotics at the most recent followup and eight were treated with long-term antibiotics due to compromised host status.
  • CONCLUSIONS: The control of infection in 18 of 20 patients using this technique compares favorably with historical success rates, which range from 24% to 100%.
  • Further research is required to analyze the individual contribution of débridement technique, the use of serial débridements, local depot antibiotics, and combination antibiotic therapy on short-term infection control rates and the long-term persistent control of periprosthetic infection.
  • LEVEL OF EVIDENCE: Level IV, therapeutic study.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Bacterial Infections / therapy. Debridement. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / therapy. Surgical Wound Infection / therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Aged, 80 and over. Arthroplasty, Replacement, Hip. Arthroplasty, Replacement, Knee. Bone Cements. Combined Modality Therapy. Drug Delivery Systems. Female. Hip Prosthesis / adverse effects. Hip Prosthesis / microbiology. Humans. Knee Prosthesis / adverse effects. Knee Prosthesis / microbiology. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Failure

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1999 Oct;81(10):1434-45 [10535593.001]
  • [Cites] Clin Orthop Relat Res. 2008 Nov;466(11):2628-33 [18781372.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):23-8 [12360003.001]
  • [Cites] Clin Orthop Relat Res. 2002 Nov;(404):125-31 [12439250.001]
  • [Cites] Clin Infect Dis. 2003 Apr 1;36(7):845-9 [12652384.001]
  • [Cites] J Arthroplasty. 2003 Oct;18(7 Suppl 1):22-6 [14560406.001]
  • [Cites] J Bone Joint Surg Am. 1974 Mar;56(2):273-84 [4452686.001]
  • [Cites] Clin Orthop Relat Res. 1976 Jun;(117):221-40 [776484.001]
  • [Cites] J Arthroplasty. 1990 Mar;5(1):35-9 [2319246.001]
  • [Cites] J Bone Joint Surg Am. 1990 Oct;72(9):1383-90 [2229118.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):105-12 [1959256.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):113-8 [1959257.001]
  • [Cites] Clin Orthop Relat Res. 1991 Dec;(273):98-104 [1959294.001]
  • [Cites] Clin Orthop Relat Res. 1992 May;(278):244-52 [1563160.001]
  • [Cites] J Bone Joint Surg Am. 1996 Apr;78(4):512-23 [8609130.001]
  • [Cites] Clin Orthop Relat Res. 1996 Oct;(331):146-50 [8895631.001]
  • [Cites] J Arthroplasty. 1996 Dec;11(8):931-8 [8986571.001]
  • [Cites] J Arthroplasty. 1997 Jun;12(4):426-33 [9195319.001]
  • [Cites] JAMA. 1998 May 20;279(19):1537-41 [9605897.001]
  • [Cites] J Bone Joint Surg Am. 1998 Sep;80(9):1306-13 [9759815.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3):161-5 [10195839.001]
  • [Cites] J Bone Joint Surg Am. 1999 May;81(5):672-83 [10360695.001]
  • [Cites] Arthroscopy. 2005 Mar;21(3):303-6 [15756183.001]
  • [Cites] J Bone Joint Surg Am. 2005 Jul;87(7):1415-22 [15995106.001]
  • [Cites] Clin Microbiol Infect. 2006 May;12(5):433-9 [16643519.001]
  • [Cites] Clin Orthop Relat Res. 2007 Aug;461:130-5 [17438469.001]
  • [Cites] J Bone Joint Surg Am. 2008 Aug;90(8):1637-43 [18676892.001]
  • [Cites] Clin Orthop Relat Res. 2002 Oct;(403):8-15 [12360001.001]
  • (PMID = 20224958.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bone Cements
  • [Other-IDs] NLM/ PMC2895840
  •  go-up   go-down


16. Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J: Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg; 2005 Apr;390(2):94-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modern series show that, in experienced hands, the standard Whipple procedure is associated with a 5-year survival of 10%-20%, with a perioperative mortality rate of less than 5%.
  • Most patients, however, will develop recurrent disease within 2 years after curative treatment.
  • This suggests the presence of micrometastases at the time of operation.
  • Adjuvant therapy has, so far, shown only modest results, with 5FU chemotherapy, to date, the only proven agent able to increase survival.
  • Nowadays, the choice of therapy should be based on histopathological assessment of the tumour.
  • Knowledge of the molecular basis of pancreatic cancer has led to various discoveries concerning its character and type.
  • Well-known examples of genetic mutations in adenocarcinoma of the pancreas are k-ras, p53, p16, DPC4.
  • Use of molecular diagnostics and markers in the assessment of tumour biology may, in future, reveal important subtypes of this type of tumour and may possibly predict the response to adjuvant therapy.
  • Defining the subtypes of pancreatic cancer will, hopefully, lead to target-specific, less toxic and finally more effective therapies.
  • Assessment of clinical benefit from surgery and adjuvant therapy should, therefore, not only be based on actuarial survival but also on progression-free survival, actual survival, median survival and quality of life (QOL) indicators.
  • Proper assessment of QOL after surgery and adjuvant therapy is of the utmost importance, as improvements in survival rates have, so far, proved to be disappointing.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Pancreatectomy. Quality of Life. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2002 Aug;35(2):180-4 [12172365.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):821-31 [9637545.001]
  • [Cites] Ann Surg. 1997 May;225(5):590-9; discussion 599-600 [9193186.001]
  • [Cites] World J Surg. 2003 Mar;27(3):324-9 [12607060.001]
  • [Cites] Surgery. 1997 Dec;122(6):989-96; discussion, 996-7 [9426411.001]
  • [Cites] Surg Gynecol Obstet. 1992 Sep;175(3):259-65 [1514162.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Br J Surg. 1991 Nov;78(11):1332-4 [1760697.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):391-8 [11296108.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):508-17 [9790340.001]
  • [Cites] Ann Surg Oncol. 2001 Mar;8(2):123-32 [11258776.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2415-32 [12805342.001]
  • [Cites] Am Surg. 1999 Jul;65(7):618-23; discussion 623-4 [10399969.001]
  • [Cites] Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5 [8857851.001]
  • [Cites] Am J Surg. 1991 Jan;161(1):120-4; discussion 124-5 [1987845.001]
  • [Cites] Mol Cancer. 2003 Sep 17;2:32 [14521721.001]
  • [Cites] Am J Surg. 1995 Jan;169(1):179-85 [7817989.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:15 [12605716.001]
  • [Cites] Pancreatology. 2001;1(5):466-71 [12120226.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]
  • [Cites] Adv Surg. 1994;27:273-84 [7908160.001]
  • [Cites] Br J Surg. 1999 May;86(5):603-7 [10361177.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):886-94 [12377342.001]
  • [Cites] Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8 [12192322.001]
  • [Cites] Int J Pancreatol. 1995 Apr;17(2):139-46 [7622937.001]
  • [Cites] World J Surg. 1995 Jul-Aug;19(4):653-9; discussion 660 [7676716.001]
  • [Cites] Arch Surg. 1989 Jul;124(7):778-81 [2742478.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):450-4 [9931396.001]
  • [Cites] Lancet. 2001 Nov 10;358(9293):1576-85 [11716884.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2920-5 [12885810.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):261-72 [8604906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):974-80 [12829132.001]
  • [Cites] Ann Surg. 2000 Jun;231(6):890-8 [10816633.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Arch Surg. 1995 Aug;130(8):838-42; discussion 842-3 [7632143.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1205-11 [12181243.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):776-82; discussion 782-4 [10615932.001]
  • [Cites] Int J Cancer. 2000 Nov 20;89(6):469-74 [11102889.001]
  • [Cites] Ann Surg. 1990 Apr;211(4):447-58 [2322039.001]
  • [Cites] Cancer. 2000 Jul 15;89(2):314-27 [10918161.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2002;9(1):1-11 [12021893.001]
  • [Cites] Surg Today. 2000;30(7):582-7 [10930222.001]
  • [Cites] Carcinogenesis. 2000 Feb;21(2):139-46 [10657949.001]
  • [Cites] J Gastrointest Surg. 2000 Nov-Dec;4(6):567-79 [11307091.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):56-61 [2354408.001]
  • [Cites] Ann Oncol. 2002 Aug;13(8):1185-91 [12181240.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):98-104 [12909221.001]
  • [Cites] Ann Surg. 1997 May;225(5):621-33; discussion 633-6 [9193189.001]
  • [Cites] Ann Surg. 1999 May;229(5):613-22; discussion 622-4 [10235519.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Am J Surg. 2003 Sep;186(3):279-86 [12946833.001]
  • [Cites] Arch Surg. 1987 May;122(5):528-32 [3579562.001]
  • [Cites] Arch Surg. 1997 Jul;132(7):771-6; discussion 777 [9230864.001]
  • [Cites] Am J Clin Oncol. 2003 Feb;26(1):30-6 [12576921.001]
  • [Cites] Ann Surg. 1987 Sep;206(3):358-65 [3632096.001]
  • [Cites] Int J Pancreatol. 1991 Oct;10(2):113-9 [1660909.001]
  • [Cites] Int J Pancreatol. 1997 Feb;21(1):65-9 [9127176.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):422-8; discussion 428 [12368670.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(2):121-7 [9745076.001]
  • [Cites] Ann Surg. 1935 Oct;102(4):763-79 [17856666.001]
  • [Cites] Surgery. 1999 Aug;126(2):178-83 [10455881.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):235-41 [9880769.001]
  • [Cites] Cancer. 2002 Aug 15;95(4 Suppl):908-11 [12209670.001]
  • [Cites] Am J Surg. 2003 Sep;186(3):264-8 [12946830.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):68-72; discussion 72-3 [8380315.001]
  • [Cites] Cancer. 1993 Oct 1;72 (7):2118-23 [8104092.001]
  • [Cites] J Gastrointest Surg. 2000 Jul-Aug;4(4):355-64; discussion 364-5 [11058853.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1261-8 [10189130.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Eur J Cancer. 1993;29A(5):698-703 [8471327.001]
  • [Cites] Ann Surg. 1988 Aug;208(2):215-20 [2840866.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):806-13 [12454519.001]
  • [Cites] J Gastrointest Surg. 2001 Jan-Feb;5(1):27-35 [11309645.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):738-45 [15492552.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] World J Surg. 1999 Sep;23(9):946-9 [10449825.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(3):269-72 [9880774.001]
  • [Cites] Cancer. 1978 Mar;41(3):880-7 [638975.001]
  • [Cites] Ann Surg. 1992 Aug;216(2):142-5 [1354435.001]
  • [Cites] Swiss Surg. 2000;6(5):275-82 [11077496.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4 Suppl 3):17-21 [12014863.001]
  • [Cites] Int J Oncol. 1998 Dec;13(6):1323-9 [9824652.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] World J Surg. 1988 Oct;12(5):663-70 [3245219.001]
  • [Cites] Ann Surg. 1993 May;217(5):430-5; discussion 435-8 [8098202.001]
  • (PMID = 15578211.001).
  • [ISSN] 1435-2443
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 89
  •  go-up   go-down


17. Rao N, Regalla DM: Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series. Clin Orthop Relat Res; 2006 Oct;451:34-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncertain efficacy of daptomycin for prosthetic joint infections: a prospective case series.
  • Daptomycin is an option for prosthetic joint infection (PJI) because it is bactericidal against gram-positive bacteria, including multiple-resistant isolates, and active against stationary-phase bacteria in biofilm present on implants.
  • To evaluate its possible utility, we prospectively monitored 12 adults with gram-positive PJI who were not candidates for vancomycin.
  • One died of an unrelated cause shortly after completing therapy.
  • Five patients had culture-confirmed failure-all due to MRSA-including two during therapy despite hardware removal and three 1 to 10 months after completing daptomycin but with retained hardware.
  • The efficacy of daptomycin 4 mg/kg/day is uncertain in patients with PJI, especially when hardware is retained.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Arthroplasty, Replacement / adverse effects. Daptomycin / therapeutic use. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / drug therapy. Staphylococcal Infections / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Staphylococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16735866.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; NWQ5N31VKK / Daptomycin
  •  go-up   go-down


18. Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M: Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from Pancreatic Cancer Registry of Japan Pancreas Society. Pancreas; 2007 Jul;35(1):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The present study investigated the clinical characteristics, treatment, and therapeutic outcomes of 115 patients registered in the Pancreatic Cancer Registry of the Japan Pancreas Society, and therapeutic plans were reviewed.
  • If ACC is unresectable or recurrent, chemotherapy is likely to prove useful.
  • Multidisciplinary therapy centering on the role of surgery will need to be established.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Female. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging / statistics & numerical data. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575544.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Talar-Wojnarowska R, Malecka-Panas E: Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med Sci Monit; 2006 Sep;12(9):RA186-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Prognosis in pancreatic cancer remains unsatisfactory due to its late clinical presentation, low surgical resectability rates, and resistance to chemotherapy.
  • Novel therapeutic strategies are needed in order to improve the prognosis of patients with PA.
  • In human pancreatic cancer, a specific sequence of oncogene and tumor suppressor gene alterations is observed, including K-ras, HER-2/neu, p16, p53, and DPC4.
  • Drugs that target these molecular abnormalities hold great promise for PA treatment in the near future.
  • The focus of this review is to evaluate the gene mutations in pancreatic cancer, with emphasis on those studies that are most important to the clinical practice.
  • Our review also summarizes current aspects of PA treatment and the differential diagnosis of pancreatic cancer and chronic pancreatitis.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / therapy. Genetic Therapy. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / therapy


20. Moran E, Masters S, Berendt AR, McLardy-Smith P, Byren I, Atkins BL: Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention. J Infect; 2007 Jul;55(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guiding empirical antibiotic therapy in orthopaedics: The microbiology of prosthetic joint infection managed by debridement, irrigation and prosthesis retention.
  • OBJECTIVES: This study describes the microbiological spectrum of prosthetic joint infection (PJI) managed by debridement, washout and retention and so guides the choice of empirical antibiotics within this patient group.
  • METHODS: We performed a retrospective review of all patients admitted to our specialist tertiary unit for PJI who were managed with debridement and irrigation or arthroscopic washout of infected prosthetic joints between 1st January 1998 and 30th April 2003.
  • Eighty-six percent of polymicrobial cultures occurred in early infections when 47% of patients grew more than one organism.
  • MSSA was the most frequently isolated organism at all time points.
  • CONCLUSIONS: Most infections involved staphylococci.
  • Most polymicrobial infections occurred in early infection.
  • A high rate of resistance to cephalosporins among Gram-negative organisms justifies the use of a broader agent such as a carbapenem in the early empirical antibiotic regime for PJI.
  • [MeSH-major] Anti-Bacterial Agents. Arthroplasty, Replacement / adverse effects. Gram-Negative Bacteria / drug effects. Joint Prosthesis / adverse effects. Prosthesis-Related Infections / drug therapy. Staphylococcus / drug effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Debridement. Female. Gram-Negative Bacterial Infections / drug therapy. Gram-Negative Bacterial Infections / microbiology. Hip Prosthesis / adverse effects. Humans. Knee Prosthesis / adverse effects. Male. Microbial Sensitivity Tests. Middle Aged. Staphylococcal Infections / microbiology. Staphylococcus aureus / drug effects. Staphylococcus aureus / isolation & purification. Therapeutic Irrigation

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343916.001).
  • [ISSN] 1532-2742
  • [Journal-full-title] The Journal of infection
  • [ISO-abbreviation] J. Infect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


21. Sohn TA, Su GH, Ryu B, Yeo CJ, Kern SE: High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells. Ann Surg; 2001 May;233(5):696-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-throughput drug screening of the DPC4 tumor-suppressor pathway in human pancreatic cancer cells.
  • OBJECTIVE: To screen a library of small chemicals for compounds that activate the DPC4 signal transduction pathway in a human pancreatic cancer cell line.
  • Specifically, DPC4 (deleted in pancreatic carcinoma, locus 4 or MADH4/SMAD4) is a tumor-suppressor gene mutated in approximately 50% of human pancreatic adenocarcinomas.
  • DPC4 plays an important role in the well-studied transforming growth factor-beta (TGFbeta) signaling pathway.
  • It would be useful to identify therapies that augment or restore the downstream functions of this critical signal transduction pathway, in hopes that such therapy would have a rational role in anticancer therapy.
  • METHODS: Using a commercially available plasmid vector with a luciferase reporter gene already incorporated, a DPC4-specific reporter construct was genetically engineered.
  • This was done by inserting six copies of the palindromic Smad binding element (6SBE), which is a DNA binding element specific for DPC4, in front of the minimal promoter in the plasmid.
  • This construct was then stably integrated into the genome of a human pancreatic cancer cell line (PANC-1) that has wild-type DPC4.
  • Several stably transfected clones were tested for basal luciferase expression and inducibility with TGFbeta, which is known to activate the DPC4 signal transduction pathway.
  • A single transfected clone was chosen for the drug screen based on basal luciferase (reporter) expression and TGFbeta inducibility.
  • A systematic screen of the chemical library was then performed, using luciferase activity to detect DPC4 activity and induction of the signaling pathway.
  • RESULTS: A high-throughput system based on this stably integrated reporter system was used to screen a library of 16,320 random compounds to identify agents that conferred robust augmentation of the DPC4 signal transduction pathway.
  • The screening identified several compounds capable of augmenting DPC4-specific luciferase reporter activity, and a specific mechanism for one compound was identified.
  • The discovery of such agents will aid our understanding of complex tumor-suppressive signaling pathways and may identify other potential therapeutic targets within this critical signaling pathway.
  • In addition, random drug screening provides an unbiased method for identifying drugs or lead compounds for potential therapeutic use.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • American Type Culture Collection. culture/stock collections - ATCC JHU-56 (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 29;286(5441):971-4 [10542155.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 24;1333(2):F105-50 [9395284.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):2002-6 [10766191.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3137-42 [10866300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9624-9 [10944227.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):755-61 [10980115.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1105-11 [11021814.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Nature. 1996 Oct 31;383(6603):832-6 [8893010.001]
  • [Cites] Gastroenterology. 1996 Nov;111(5):1369-72 [8898652.001]
  • [Cites] Oncogene. 1997 Apr 24;14(16):1891-9 [9150356.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13690-6 [9153220.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):3929-34 [9307274.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24731-4 [9312063.001]
  • [Cites] Nature. 1997 Dec 4;390(6659):465-71 [9393997.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1124-6 [9515793.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):188-94 [9561843.001]
  • [Cites] Genes Dev. 1998 Aug 15;12(16):2445-62 [9716398.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4592-7 [9788608.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5329-32 [9850059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1427-32 [9990040.001]
  • [Cites] Science. 1999 Sep 10;285(5434):1733-7 [10481009.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):37-43 [10623651.001]
  • (PMID = 11323508.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01-CA62694
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Trans-Activators; 0 / Transforming Growth Factor beta; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1421310
  •  go-up   go-down


22. Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K: Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas; 2004 Apr;28(3):219-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preoperative histologic diagnosis and diagnostic imaging are fundamentals in managing the disease, but it is not rare to find unexpected peritoneal dissemination or liver metastasis at the time of operation.
  • Multidisciplinary treatments combined with surgery were performed, and various effects of postoperative chemotherapy after pancreatectomy, intraoperative- and postoperative-radiation therapy, or postoperative chemotherapy for unresectable tumor, were shown.
  • Development of unconventional therapies and refinement of the conventional therapy should be promoted on a randomized prospective trial basis.
  • To promote this effort, which requires the international comparisons and cooperation, JPS developed a computerized JPS registration system downloadable from the JPS website (http://www.kojin.or.jp/suizou/index.html).
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy. Registries
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Combined Modality Therapy. Female. Humans. Japan. Lymph Node Excision. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pancreatectomy. Prognosis. Survival Analysis


23. Han SH, Lee DB, Lee DW, Kim EH, Yoon BS: Ultra-rapid real-time PCR for the detection of Paenibacillus larvae, the causative agent of American Foulbrood (AFB). J Invertebr Pathol; 2008 Sep;99(1):8-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultra-rapid real-time PCR for the detection of Paenibacillus larvae, the causative agent of American Foulbrood (AFB).
  • A novel micro-PCR-based detection method, termed ultra-rapid real-time PCR, was applied to the development of a rapid detection for Paenibacillus larvae (P. larvae) which is the causative agent of American Foulbrood (AFB).
  • This method was designed to detect the 16S rRNA gene of P. larvae with a micro-scale chip-based real-time PCR system, GenSpector TMC-1000, which has uncommonly fast heating and cooling rates (10 degrees C per second) and small reaction volume (6microl).
  • In the application of ultra-rapid real-time PCR detection to an AFB-infected larva, the minimum detection time was 7 min and 54s total reaction time (30 cycles), including the melting temperature analysis.
  • To the best of our knowledge, this novel detection method is one of the most rapid real-time PCR-based detection tools.
  • [MeSH-major] Bacillaceae / isolation & purification. Bees / microbiology. Gram-Positive Bacterial Infections / veterinary. Polymerase Chain Reaction / methods
  • [MeSH-minor] Animals. DNA, Bacterial / analysis. Host-Pathogen Interactions. Larva / microbiology. Reproducibility of Results. Sensitivity and Specificity. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571197.001).
  • [ISSN] 1096-0805
  • [Journal-full-title] Journal of invertebrate pathology
  • [ISO-abbreviation] J. Invertebr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial
  •  go-up   go-down


24. Voutsadakis IA: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med; 2007 Mar-Apr;11(2):252-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2.
  • High up in the list of colorectal cancer lesions are APC (adenomatous polyposis coli), K-ras, Smad4 (or DPC4-deleted in pancreatic cancer 4) and p53 genes.
  • UPS inhibition has been found to be a pre-requisite for apoptosis and is already clinically exploited with the proteasome inhibitor bortezomib in multiple myeloma.
  • Inhibition of Cox-2 by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been found to inhibit proliferation of colorectal cancer cells and in epidemiologic studies has been shown to reduce colon polyp formation in genetically predisposed populations and in the general population.
  • Targeted therapies, the result of increasingly understanding carcinogenesis in the molecular level, have entered the field of anti-neoplastic treatment and are used by themselves and in combination with chemotherapy drugs.
  • Combinations of targeted drugs have started also to be investigated.
  • This article reviews the molecular pathogenesis of colorectal cancer, the roles of UPS and Cox-2 in it and puts forward a rational for their combined inhibition in colorectal cancer treatment.
  • [MeSH-major] Carcinoma / therapy. Colorectal Neoplasms / therapy. Cyclooxygenase 2 / metabolism. Cyclooxygenase Inhibitors / therapeutic use. Proteasome Endopeptidase Complex / metabolism. Ubiquitin / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488476.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Cyclooxygenase Inhibitors; 0 / Ubiquitin; EC 1.14.99.1 / Cyclooxygenase 2; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 298
  • [Other-IDs] NLM/ PMC3822826
  •  go-up   go-down


25. Shimoyama M: [Guideline for phase I study on new anticancer agents]. Gan To Kagaku Ryoho; 2001 Feb;28(2):261-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since more than 50% of patients with cancer could no be cured by present standard therapy, new effective anticancer agents are needed in clinical level.
  • This paper shows major parts of a report entitled "Guideline for phase I study on new anticancer agents", already published in JPs Pharmacol Ther 26: 441-454, 1998, with minor modification in order to answer these issues.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Clinical Trials, Phase I as Topic / standards
  • [MeSH-minor] Humans. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242659.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


26. Doi R, Kami K, Ito D, Kawaguchi Y, Uemoto S, Yoshida S: [Surgical treatment of carcinoma of the pancreas]. Nihon Geka Gakkai Zasshi; 2006 Jul;107(4):168-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of carcinoma of the pancreas].
  • Invasive ductal carcinoma of the pancreas (pancreatic cancer) is mainly treated by operative resection, radio-chemotherapy, or chemotherapy.
  • The survival rate of the patients with each treatment is not good when compared with that in other cancers.
  • In addition, the volume of pancreatic cancer patients treated at the institution and the surgeon's personal experience may greatly affect the decision.
  • A recent randomized clinical trial from Japan revealed that surgical resection has a survival advantage over chemo-radiation therapy for locally advanced pancreatic cancer, which is defined as stage IVa in the fourth Japanese edition of the Classification of Pancreatic Carcinoma.
  • In addition, the surgical indications should be reevaluated in combination with the adjuvant or neoadjuvant chemotherapy in future.
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Survival Rate

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16878408.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 7
  •  go-up   go-down


27. Schäfer P, Fink B, Sandow D, Margull A, Berger I, Frommelt L: Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. Clin Infect Dis; 2008 Dec 1;47(11):1403-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy.
  • BACKGROUND: The value of microbiological culture to diagnose late periprosthetic infection is limited, especially because standard methods may fail to detect biofilm-forming sessile or other fastidious bacteria.
  • This study was designed to assess the duration of culture that is necessary for reliable detection.
  • PATIENTS AND METHODS: Ten periprosthetic tissue specimens each were obtained during revision from 284 patients with suspected late hip or knee arthroplasty infection.
  • To define infection, a pre-established algorithm was used; this included detection of indistinguishable organisms in >/=2 tissue samples or growth in 1 tissue sample and a positive result of histologic analysis (>5 neutrophils in at least 10 high-power fields).
  • The time to detection of organisms was monitored.
  • RESULTS: Infection was diagnosed in 110 patients.
  • After 7 days (the longest incubation period most frequently reported), the detection rate via culture was merely 73.6%.
  • Organisms indicating infection were found for up to 13 days.
  • In both populations, an unequivocal correlation between the number of culture-positive tissue samples and positive results of histologic analysis was noted, which corroborated the evidence that true infections were detected over the entire cultivation period.
  • CONCLUSIONS: Prolonged microbiological culture for 2 weeks is promising because it yields signs of periprosthetic infection in a significant proportion of patients that would otherwise remain unidentified.
  • [MeSH-major] Arthritis / diagnosis. Bacterial Infections / diagnosis. Bacteriological Techniques. Hip / microbiology. Knee / microbiology. Prosthesis-Related Infections / diagnosis
  • [MeSH-minor] Aged. Bacteria / isolation & purification. Female. Humans. Male. Statistics as Topic. Time Factors






Advertisement